Colesevelam
- Generic Name
- Colesevelam
- Brand Names
- Cholestagel, Lodalis, Welchol
- Drug Type
- Small Molecule
- CAS Number
- 182815-43-6
- Unique Ingredient Identifier
- 1XU104G55N
- Background
Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol.
- Indication
用于以胆固醇升高为主的高脂血症，当饮食和锻炼不能良好达到效果者，可单独使用或与他汀类合用。
- Associated Conditions
- Heterozygous Familial Hypercholesterolemia (HeFH), Hyperlipidemias, Type 2 Diabetes Mellitus, Primary Hyperlipidemia
Metabolic Effects of Endogenous Bile Acids After Gastric Bypass Surgery
- Conditions
- Bariatric Surgery CandidateBile Acid, Elevated SerumGlucose Metabolism Disorders
- Interventions
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT06925997
- Locations
- 🇩🇰
Department of Medicine, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark
Impact of Therapy Using Colesevelam Treatment Reducing Bile Acids in Patients With Fontan Circulation.
- Conditions
- Fontan Circulation
- Interventions
- Other: Control Arm
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- St. Boniface Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06197763
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib
- Conditions
- Hormone Receptor PositiveHER2 Positive Breast CancerEarly-stage Breast Cancer
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 177
- Registration Number
- NCT05252988
- Locations
- 🇪🇸
Hospital General Universitario de Elche, Elche, Alicante, Spain
🇪🇸Hospital Costa del Sol, Málaga, Andalucía, Spain
🇪🇸Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain
Treatment of Bile Acid Malabsorption With Liraglutide
- Conditions
- Bile Acid Malabsorption
- Interventions
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Filip Krag Knop
- Target Recruit Count
- 52
- Registration Number
- NCT03955575
- Locations
- 🇩🇰
Gentofte Hospital, Hellerup, Regionh, Denmark
Effect of the Sequestrant Colesevelam in Bile Acid Diarrhoea
- Conditions
- Chronic DiarrheaBile Acid Malabsorption
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Lars Kristian Munck
- Target Recruit Count
- 255
- Registration Number
- NCT03876717
- Locations
- 🇩🇰
Aalborg University Hospital, Aalborg, Denmark
🇩🇰Aarhus University Hospital, Aarhus, Denmark
🇩🇰Hvidovre University Hospital, Hvidovre, Denmark
Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT03856970
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
A Study of Colesevelam for Lenalidomide-Associated Diarrhea
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT03767257
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 495
- Registration Number
- NCT03561090
- Locations
- 🇺🇸
Advanced Research Institute, Ogden, Utah, United States
🇺🇸Medication Management LLC, Greensboro, North Carolina, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 609
- Registration Number
- NCT03561883
- Locations
- 🇺🇸
Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States
🇺🇸Carolina Digestive Diseases, Greenville, North Carolina, United States
🇺🇸Morristown Medical Center, Morristown, New Jersey, United States
Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption
- Conditions
- Chronic DiarrheaIrritable Bowel Syndrome With DiarrheaBile Acid Malabsorption
- Interventions
- Other: Placebo
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT03270085
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.